Moderna, Inc.,(MRNA 72.50) a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases.
As the market is tanking because of worsening global Covid-19 infections, MRNA may the hope to solve the problem. Its stock may be the bright spot on a downtrending market.I am adding MRNA to my diversified portfolio now consists of MRNA,PAA, MRO, CNR, AGQ, FCX, SQ, PINS, SRNE, TGT and NKLA. You may search these symbol in this blog for more details. The following are near term catalysts for MRNA stock price.
。Moderna is prepping for the global launch of its potential coronavirus vaccine, already taking in $1.1 billion in deposits from governments, the company said Thursday.
。MRNA reported a wider-than-expected loss of 59 cents a share for Q3. But revenue surged 826% to $157.91 million, nearly double analyst forecasts.
。Moderna's mRNA-1273 together with Pfizer and German biotech partner BioNTech's BNT162b2 are the only two coronavirus vaccine candidates that have a reasonable chance of winning Food and Drug Administration (FDA) Emergency Use Authorization (EUA) by the end of this year. Moderna expects to have enough data to submit for EUA by Nov. 25, 2020.
。Pfizer CEO Albert Bourla said in the company's third-quarter conference call on Tuesday that an interim efficacy analysis for a late-stage study of BNT162b2 still hasn't been performed by the study's independent data monitoring committee. Bad news for PFE is good news for MRNA. This may push MRNA up as the first to announce vaccine approval.
Pipelines：
In addition to developing vaccines for influenza and COVID-19, Moderna has a broad pipeline of candidates. With a platform that essentially rewrites genetic instructions, the applications are almost limitless. The pipeline contains treatments for ailments as varied as heart failure, autoimmune disorders, tumors associated with multiple cancers, and hepatitis. Moderna's vaccine pipeline for treatment of varies ailment are : 1 in phase III, 3 in phase II and 5 in phase 1.
Analysts opinions:
Analysts consensus rating is 2.1 out of 5. Consensus price target is 92.54 while low and high price targets are 42 and 136 respectively.
Technicals: Bullish Cup and Handle bottom in the making. Next two resistances are 81.37 and 92.51. Support is 65.
临床阶段生物技术公司Moderna，Inc.（MRNA 72.50）开发基于信使RNA的疗法和疫苗，用于治疗传染病，免疫肿瘤学，罕见病和心血管疾病。
由于全球Covid-19感染情况恶化导致股市不景气，而MRNA有望解决这个问题。它的股票可能是下降趋势市场上的亮点。我将MRNA添加到我的多元化投资组合中，现在包括MRNA，PAA，MRO，CNR，AGQ，FCX，SQ，PINS，SRNE，TGT和NKLA。 您可以在此博客中搜索这些符号以获取更多详细信息。以下是MRNA股票价格的近期催化剂。
。该公司周四表示，Moderna正准备在全球范围内推出其潜在的冠状病毒疫苗，该疫苗已从各国政府手中吸收了11亿美元的订金。
。MRNA报告第三季度每股亏损59美分，超出了亏损预期。但营收增长了826％，至1.5991亿美元，几乎是分析师预期的两倍。
。Moderna的mRNA-1273与辉瑞公司以及德国生物技术合作伙伴BioNTech的BNT162b2一起，是仅有的两种冠状病毒疫苗候选药物有望在今年年底前获得食品药品管理局（FDA）的紧急使用授权（EUA）。 Moderna预计到2020年11月25日将有足够的数据提交EUA。
。辉瑞公司首席执行官阿尔伯特·布尔拉（Albert Bourla）在周二的公司第三季度电话会议上表示，该研究的独立数据监控委员会尚未对BNT162b2的后期研究进行中期疗效分析。PFE的坏消息对MRNA来说是个好消息。这可能会推动MRNA成为第一个宣布疫苗被通过的公司。
。在研发中的药物产品线：
除了开发用于流感和COVID-19的疫苗外，Moderna还拥有大量候选药物。利用实质上重写遗传指令的平台，应用程序几乎是无限的。该管道包含各种疾病的治疗方法，例如心力衰竭，自身免疫性疾病，与多种癌症相关的肿瘤和肝炎。用于治疗各种疾病的Moderna疫苗产品线的研发阶段有：第三阶段有1种，第二阶段有3种，第一阶段有5种。
。分析师意见：
分析师的共识评级为5分中的2.1为买入评级。共识目标价为92.54，最低和最高目标价分别为42和136。
。技术因素：看涨的杯状底部图形正在造成中。接下来的两个阻力是81.37和92.51。支撑是65.
No comments:
Post a Comment